Q2 FY24 Financial Highlights

India: Amplifying our Core Lupin prescription business is positioned to outperform IPM with key drivers in place Enhancing penetration and reach Maximizing Chronic therapy focus • Sales force expansion • Grow Biosimilars Inorganic Strategy Target M&A/ inorganic activities - mid size companies, brands & portfolios New Product Pipeline • In-house pipeline of novel assets In-license via partnerships Expanding footprint • Partnering in e-commerce, organized retail and institutional business Business Verticals LUPIN Enabling end to end healthcare ecosystem and access for the patient Empowering community LUPIN LIFE Life inspired try Science CHC Portfolio catering to GI, VMS, Cough/cold therapies Diagnostics platform expanding across India LUPIN DIAGNOSTICS Good health starts here LiFE ATHARV ABILITY A LUPIN INITIATIVE ABILITY-DIGNITY-LIF Going beyond the pill with digital offering and patient neuro-rehab Building capacity of HCPs and empowering patients by education and PSPs¹ Digitally assisting retailers and channel partners SCIFLIX HUMRAHI pharmarack 1 PSPs Patient Support Program 8

View entire presentation